A New Hope for a Rare Heart Condition: What the FDA's Latest Approval Means for Patients

The Food and Drug Administration has approved aficamten (Myqorzo), a groundbreaking new treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first major advancement in decades for this rare heart condition. This oral medication offers new hope for patients who have long relied on older treatments like beta-blockers or invasive procedures.

What Is Obstructive Hypertrophic Cardiomyopathy?

Obstructive hypertrophic cardiomyopathy is a condition where the heart muscle becomes abnormally thick, creating a blockage in the left ventricular outflow tract—essentially making it harder for blood to flow out of the heart. This leads to symptoms like shortness of breath, chest pain, and reduced exercise capacity. The condition affects thousands of Americans and has historically been challenging to treat effectively.

How Does This New Treatment Work?

Aficamten works as a cardiac myosin inhibitor, specifically targeting the heart's overactive contractions that characterize this condition. Unlike previous treatments that simply managed symptoms, this medication directly addresses the underlying problem by reducing hypercontractility and left ventricular outflow tract obstruction—the hallmark features of oHCM.

The approval was based on compelling results from two major clinical trials. In the SEQUOIA-HCM study, patients taking aficamten showed a significant improvement in peak oxygen uptake of 1.8 ml per kilogram compared to no improvement with placebo after 24 weeks. The MAPLE-HCM trial went further, comparing aficamten directly to metoprolol, a long-standing first-line therapy, and found superior improvements in exercise capacity and multiple other measures.

What Are the Key Benefits and Considerations?

The clinical trials revealed several important advantages of this new treatment:

• Exercise Capacity: Patients experienced meaningful improvements in their ability to exercise and perform daily activities, as measured by peak oxygen uptake tests
• Symptom Relief: Participants achieved significant gains in New York Heart Association functional class scores and Kansas City Cardiomyopathy Questionnaire clinical summary scores, reflecting real improvements in daily symptoms and overall health status
• Broader Effectiveness: The MAPLE-HCM study showed the drug works effectively even in patients with less severe disease, expanding the potential patient population who could benefit

However, the medication comes with important safety considerations. The FDA has required a boxed warning for heart failure due to systolic dysfunction, and patients will need regular echocardiographic monitoring before and during therapy. Treatment isn't recommended for patients with a left ventricular ejection fraction below 55%, and dose adjustments may be necessary if heart function declines.

"Living with symptomatic obstructive HCM means managing physical limitations and burdensome symptoms every day of your life," said Lisa Salberg, founder and CEO of the Hypertrophic Cardiomyopathy Association. "For far too long, we've had few options to address our needs, and the approval of MYQORZO is a long-awaited and major addition to bring new hope to patients living with oHCM."

Due to these safety considerations, aficamten will only be available through a restricted Risk Evaluation and Mitigation Strategy program, ensuring proper monitoring and patient safety. The medication is expected to become available in the United States in the second half of January 2026, with patient support offered through the company's Myqorzo & You program.

This approval represents a significant milestone for the estimated thousands of Americans living with obstructive hypertrophic cardiomyopathy, offering the first new pharmacologic option specifically designed to target the underlying mechanisms of their condition rather than just managing symptoms.